The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

about

Bone health in HIV and hepatitis B or C infections The protease inhibitors and HIV-associated bone loss.Management of bone mineral density in HIV-infected patients.Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?Bone Loss in HIV Infection.

P2860

Q30238946-9278F9AC-32A7-40D6-B71E-FF97DE3476AC Q36818259-8A4DAAD2-CA0C-4DBF-BD25-FD13C588E7D4 Q38711437-01B83B01-5BCF-46C9-906B-6B8C2D740B64 Q38818789-F4E29816-FD5B-4406-BA5A-01F22A3001EA Q38835028-645AE677-BB46-4472-97BC-2E9DC2006C48

P2860

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

Item

http://www.wikidata.org/entity/Q37279429

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 July 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The ASSURE study: HIV-1 suppre ...... acavir/lamivudine + atazanavir

@en

The ASSURE study: HIV-1 suppre ...... cavir/lamivudine + atazanavir.

@nl

type

Item

label

The ASSURE study: HIV-1 suppre ...... acavir/lamivudine + atazanavir

@en

The ASSURE study: HIV-1 suppre ...... cavir/lamivudine + atazanavir.

@nl

prefLabel

The ASSURE study: HIV-1 suppre ...... acavir/lamivudine + atazanavir

@en

The ASSURE study: HIV-1 suppre ...... cavir/lamivudine + atazanavir.

@nl

P1476

The ASSURE study: HIV-1 suppre ...... acavir/lamivudine + atazanavir

@en

P2093

C B Small

http://www.w3.org/2001/XMLSchema#string

D A Margolis

http://www.w3.org/2001/XMLSchema#string

D A Wohl

http://www.w3.org/2001/XMLSchema#string

E DeJesus

http://www.w3.org/2001/XMLSchema#string

H Edelstein

http://www.w3.org/2001/XMLSchema#string

H H Zhao

http://www.w3.org/2001/XMLSchema#string

L Bhatti

http://www.w3.org/2001/XMLSchema#string

L L Ross

http://www.w3.org/2001/XMLSchema#string

M S Shaefer

http://www.w3.org/2001/XMLSchema#string

W G Weinberg

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

P304

106-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIV.12281

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26176344

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5034844

http://www.w3.org/2001/XMLSchema#string

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

about

P2860

P2860

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932